INTERMACS: June 2006 – December 2012: CMS Report
Adults: n=7849
All primary implants as of 12/31/2012
n= 7928
Pediatric patients: n=79
(patients < 19 yrs of age at time of implant)
Continuous Flow
n=6732
Pulsatile flown=1117
CFLVADn=6550
CFBi-VADn=182
1Figure 1
INTERMACS: June 2006– December 2012: CMS Report
2Figure 2
2011-2012Total Implants: 5083Total Enrolled: 4592 (90.3%)
INTERMACS Hospitals
Adult Primary Continuous Flow LVAD/BiVADs, n=6732 By Age Groups
Months post implant
Event: Death (censored at transplant and recovery)
% S
urv
ival
Grp 1: < 50 yrs, n= 1758Deaths=293
INTERMACS: June 2006 – December 2012: CMS Report
Grp 2: 50–64 yrs, n= 3054Deaths=648
Grp 3: 65-69 yrs, n= 1030Deaths= 275
Overall p < .0001
3
Grp 4: 70+ yrs, n= 889Deaths= 268
Figure 3
Adult Primary Continuous Flow LVAD/BiVADs, n=6732 By Age Groups
Months post implant
Event: Death (censored at transplant and recovery)
% S
urv
ival
Grp 1: < 65 yrs, n= 4812Deaths=941
INTERMACS: June 2006 – December 2012: CMS Report
Grp 2: 65+ yrs, n= 1919Deaths=543
p < .0001
4Figure 4
Adult Primary Continuous Flow LVAD/BiVADs, n=6732 By Total Center Volume* for 2011 and 2012
Months post implant
Event: Death (censored at transplant and recovery)
% S
urv
ival
Grp 1: 1-12 implants, n= 147Deaths=22
INTERMACS: June 2006 – December 2012: CMS Report
Grp 2: 13-32 implants, n= 1008Deaths=227
Grp 3: 33-56 implants, n= 2084Deaths= 456
Overall p = .17
5
Grp 4: 57-149 implants, n= 3486Deaths= 776
* Center volume is the total implants of FDA approved durable MCSDs implanted during 2011 and 2012
(14) (4)
Figure 5
Adult Primary Continuous Flow LVAD/BiVADs, n=6732 By Total Center Volume* for 2011 and 2012
Months post implant
Event: Death (censored at transplant and recovery)
% S
urv
ival
Grp 1: 1-12 implants, n= 62, Deaths=17
INTERMACS: June 2006 – December 2012: CMS Report
Grp 2: 13-32 implants, n=290, Deaths=83
Grp 3: 33-56 implants, n=528, Deaths=154
Overall p = .54
6
Grp 4: 57-149 implants, n=1038, Deaths=288
* Center volume is the total implants of FDA approved durable MCSDs implanted during 2011 and 2012
Age (yrs) ≥ 65
Figure 6
Adult Primary Continuous Flow LVAD/BiVADs, n=6732 By Total Center Volume* for 2011 and 2012
Months post implant
Event: Death (censored at transplant and recovery)
% S
urv
ival
Grp 1: 1-12 implants, n= 127Deaths=20
INTERMACS: March 2009 – December 2012: CMS Report
Grp 2: 13-32 implants, n= 946Deaths=214
Grp 3: 33-56 implants, n= 2084Deaths= 456
Overall p = .21
7
Grp 4: 57-149 implants, n= 3486Deaths= 776
DT Centers
* Center volume is the total implants of FDA approved durable MCSDs implanted during 2011 and 2012Figure 7
Adult Primary Continuous Flow LVAD/BiVADs, n=6732 By Total Center Volume* for 2011 and 2012
Months post implant
Event: Death (censored at transplant and recovery)
% S
urv
ival
Grp 1: 1-12 implants, n= 83Deaths=12
INTERMACS: June 2006 – December 2012: CMS Report
Grp 2: 13-32 implants, n= 823Deaths=191
Grp 3: 33-56 implants, n= 2084Deaths= 456
Overall p = .14
8
Grp 4: 57-149 implants, n= 3486Deaths= 776
TX Centers
* Center volume is the total implants of FDA approved durable MCSDs implanted during 2011 and 2012Figure 8
Adult Primary Continuous Flow LVAD/BiVADs, n=6732 By DT Center
Months post implant
Event: Death (censored at transplant and recovery)
% S
urv
ival
Not a DT Center, n= 88Deaths=19
INTERMACS: June 2006 – December 2012: CMS Report
DT Center, n= 6643Deaths=1466
Overall p = .54
9Figure 9
Adult Primary Continuous Flow LVAD/BiVADs, n=6732 By TX Center
Months post implant
Event: Death (censored at transplant and recovery)
% S
urv
ival
Not a TX Center, n= 255Deaths=49
INTERMACS: June 2006 – December 2012: CMS Report
TX Center, n= 6476Deaths=1435
Overall p = .52
10Figure 10
Adult Primary Continuous Flow LVAD/BiVADs, n=6732 By DT and/or TX Center
Months post implant
Event: Death (censored at transplant and recovery)
% S
urv
ival
Grp 1: DT and TX Center, n=6435, deaths=1425
INTERMACS: June 2006 – December 2012: CMS Report
Grp 2: DT Center (not TX Ctr), n=208, deaths=41
Overall p = .53Grp 1 v 2: p=.40Grp 1 v 3: p=.22Grp 1 v 4: p=.81Grp 2 v 3: p=.62Grp 2 v 4: p=.64Grp 3 v 4: p=.48
11
Grp 3: TX Center (not DT Ctr), n=41, deaths=10
Grp 4: Not DT Ctr, Not TX Ctr, n=47, deaths=8
Figure 11
Adult Primary Continuous Flow LVAD/BiVADs, n=6732 By Device Strategy
Months post implant
Event: Death (censored at transplant and recovery)
% S
urv
ival
Grp 1: BTT, n= 1875Deaths=317
INTERMACS: June 2006– December 2012: CMS Report
Grp 2: BTC, n= 2517Deaths=540
Grp 3: DT, n= 2250Deaths= 606
Overall p = .14
12
Grp 4: Other*, n= 89Deaths= 21
*For overall “Other” Device strategies at time of implant include 40 bridge to recoveries, 21 Rescue therapy and 28 Others
Figure 12
Adult Primary Continuous Flow LVAD/BiVADs, n=6732 By Device Strategy
Months post implant
Event: Death (censored at transplant and recovery)
% S
urv
ival
Grp 1: BTT, n= 276Deaths=62
INTERMACS: June 2006– December 2012: CMS Report
Grp 2: BTC, n= 399Deaths=116
Grp 3: DT, n= 1232Deaths=361
Overall p = .24
13
Grp 4: Other*, n= 12Deaths= 4
Age (yrs) ≥ 65
*For overall “Other” Device strategies at time of implant include 40 bridge to recoveries, 21 Rescue therapy and 28 Others
Figure 13
Adult Primary Continuous Flow LVAD/BiVADs, n=6732 By Device Type
Months post implant
Event: Death (censored at transplant and recovery)
% S
urv
ival
CFLVADs n= 6549Deaths=1406
INTERMACS: June 2006– December 2012: CMS Report
CFBi-VADs, n= 182Deaths=78
P < .0001
14
% SurvivalMonths LVAD BiVAD1 96% 77%3 91% 69%6 87% 65%12 81% 59%24 70% 54%
Figure 14
Adult Primary Continuous Flow LVAD/BiVADs, n=6732 By Device Type
Months post implant
Event: Death (censored at transplant and recovery)
% S
urv
ival
CFLVADs n= 1875Deaths=515
INTERMACS: June 2006– December 2012: CMS Report
CFBi-VADs, n= 44Deaths=28 P < .0001
15
% SurvivalMonths LVAD BiVAD1 94% 58%3 88% 51%6 83% 48%12 75% 41%24 63% 38%
Age (yrs) ≥ 65
Figure 15
Adult Primary Continuous Flow LVAD/BiVADs, n=6732
INTERMACS: June 2006– December 2012: CMS Report
16
Age (yrs) < 65(n=4813)
Age (yrs) ≥ 65(n=1919)
Alive (device in place)
Transplanted
Dead
Recovery
39%
38%
22%
1%
Alive (device in place)
Transplanted
Dead
Recovery
16%
50%
34%
0.4%
Months post implant Months post implant
Pro
port
ion
of p
atie
nts
Pro
port
ion
of p
atie
nts
Figure 16
(a) (b)
Adult Primary Continuous Flow LVAD/BiVADs, n=6732
INTERMACS: June 2006– December 2012: CMS Report
17
DT Centers(n=6643)
Not DT Center(n=88)
Alive (device in place)
Transplanted
Dead
Recovery
32%
42%
25%
1%
Alive (device in place)
Transplanted
Dead
Recovery
35%
42%
21%
2%
Months post implant Months post implant
Pro
port
ion
of p
atie
nts
Pro
port
ion
of p
atie
nts
Figure 17
(a) (b)
Top Related